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Abstract
Background: Primary central nervous system lymphoma (PCNSL) is a highly aggressive Non-Hodgkin lymphoma
(NHL) with rising incidence over the past 30 years in immunocompetent patients. Although outcomes have
improved, PCNSL is still associated with inferior prognosis compared to systemic NHL. Many questions regarding
the optimal therapeutic approach remain unanswered.
Methods/Design: This is a randomized, open-label, international phase III trial with two parallel arms. We will recruit 250
patients with newly diagnosed PCNSL from approximately 35 centers within the networks of the German Cooperative
PCNSL study group and the International Extranodal Lymphoma Study Group. All enrolled patients will undergo
induction chemotherapy consisting of 4 cycles of rituximab 375 mg/m2/d (days 0 & 5), methotrexate 3.5 g/m2 (d1),
cytarabine 2 × 2 g/m2/d (d2-3), and thiotepa 30 mg/m2 (d4) every 21 days. All patients will undergo stem-cell harvest
after the second cycle. After 4 cycles of induction chemotherapy, patients achieving partial or complete response will
be centrally randomized to 2 different consolidation treatments: (A) conventional-dose immuno chemotherapy with
rituximab 375 mg/m2 (d0), dexamethasone 40 mg/d (d1-3), etoposide 100 mg/m2/d (d1-3), ifosfamide 1500 mg/m2/d
(d1-3) and carboplatin 300 mg/m2 (d1) (R-DeVIC) or (B) high-dose chemotherapy with BCNU (or busulfan) and thiotepa
followed by autologous stem cell transplantation (HCT-ASCT). The objective is to demonstrate superiority of HCT-ASCT
compared to R-DeVIC with respect to progression-free survival (PFS, primary endpoint). Secondary endpoints include
overall survival (OS), treatment response and treatment-related morbidities. Minimal follow-up after treatment completion
is 24 months.
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Discussion: The rationale for consolidation treatment in PCNSL is to eliminate residual lymphoma cells and to decrease
the risk for relapse. This can be achieved by agents crossing the blood brain barrier either applied at conventional doses
or at high doses requiring autologous stem cell support. HCT-ASCT has been shown to be feasible and highly
effective in patients with newly-diagnosed PCNSL. However, it is unclear whether HCT-ASCT is really superior
compared to conventional-dose chemotherapy after an intensified antimetabolites-based immunochemotherapy
in patients with newly-diagnosed PCNSL. To answer this question, we designed this investigator initiated
randomized phase III trial.
Trial registration: German clinical trials registry DRKS00005503 registered 22 April 2014 and ClinicalTrials.gov
NCT02531841 registered 24 August 2015.
Keywords: Primary central nervous system lymphoma (PCNSL), High-dose chemotherapy (HDT), Autologous stem
cell transplantation (ASCT), Conventional chemotherapy, Randomized controlled trial
Background
Primary CNS lymphoma (PCNSL) accounts for 1 to 2 %
of all Non-Hodgkin’s lymphomas (NHL) and for 2 to
7 % of all primary CNS tumors. Its incidence has in-
creased over the past 30 years.
Prognosis without treatment resembles that of systemic
high-grade NHL, with a median survival of approximately
3 months. Although therapy has improved the outcome of
patients with PCNSL, prospective clinical trials are rare
compared to systemic NHL and many questions regarding
the optimal therapeutic approach remain unanswered. Cur-
rently, high-dose methotrexate (HD-MTX) is considered
the most efficient known cytostatic agent for PCNSL [1, 2].
Several drugs have been combined with HD-MTX to
improve outcome, but only one randomized trial demon-
strated superiority of additional high-dose cytarabin (HD-
AraC) compared to single agent HD-MTX treatment so far
[3]. Other agents such as lomustine, procarbazine, vinca
alkaloids, temozolomide and thiotepa have also been added
to HD-MTX, revealing promising remission rates and ac-
ceptable toxicity profiles. A single-arm phase II trial asses-
sing the chemotherapy combination named “MATILDE”
has included thiotepa [4], resulting in an overall response
rate (ORR) of 72 % and a complete remission rate (CRR) of
46 %, with a 5-year survival of 42 %. The use of thiotepa is
justified by its excellent bioavailability in the CNS and its
high efficacy in aggressive lymphoma and in reported
trials on PCNSL [4–6]. Rituximab in addition to systemic
chemotherapy is the current standard for treating systemic
B-cell lymphomas [7]. First results of the randomized
phase II International Extranodal Lymphoma Study
Group (IELSG) 32 trial show a significant improvement of
response, failure free survival and overall survival by the
addition of rituximab to standard HD-MTX/HD-AraC.
Further addition of thiotepa to HD-MTX/HD-AraC shows
even further improvement, but not reaching statistical sig-
nificance [8].
Recent trials have demonstrated that consolidating
strategies with non-cross-resistant cytostatic agents in
first-line therapy yield promising results in treating
PCNSL [9]. Another regimen with dexamethasone, etopo-
side, ifosfamide and carboplatin (DeVIC) has been applied
in recurrent/refractory and in newly-diagnosed PCNSL
with good results. A retrospective analysis of 21 patients
with newly-diagnosed PCNSL who received DeVIC chemo-
therapy followed by whole brain radiation therapy (WBRT)
showed high efficacy with ORR to chemotherapy (DeVIC)
of 95 % in newly-diagnosed PCNSL and 83 % in refractory
and recurrent PCNSL [10].
Based on experience in other hematological malig-
nancies, such as relapsed systemic diffuse large B-cell
lymphoma, and the need for effective consolidation
treatment, high-dose chemotherapy supported by au-
tologous stem cell transplantation (HDT-ASCT) has
also been investigated in PCNSL. The rationale for
HDT-ASCT in PCNSL is to achieve therapeutic drug
concentration in the CNS tissues and sanctuaries, and
to overcome chemo resistance [11, 12]. In recent trials,
we demonstrated a high rate of long-lasting remissions in
PCNSL patients treated with HDT-ASCT, with or without
WBRT [5, 6]. In a pilot and phase-II study, we treated 30
patients with PCNSL ≤65 years with sequential induction
chemotherapy including three cycles of HD-MTX, HD-
AraC, and thiotepa followed by stem-cell harvest. The con-
ditioning regimen consisted of carmustine and thiotepa
followed by ASCT; WBRT was given as consolidation [5].
Twenty-three of the 30 patients proceeded to HDT-ASCT
resulting in complete remission (CR) and partial remission
(PR) in 15 and 8 patients, respectively. With a median
follow-up of 63 months, the 5-year OS was 69 % for all
patients and 87 % for those completing HDT-ASCT. In a
further trial, induction chemotherapy has been intensified,
thiotepa dose was doubled, and only those patients not
achieving CR after induction therapy underwent WBRT
(“Freiburg Protocol”) [6]. Seven of 11 patients were in CR
following ASCT, and three in PR underwent post-ASCT
radiotherapy. After a median follow-up of 25 months, 3-
year OS was 77 %. None of the patients suffered from
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severe neurotoxicity during the follow-up period. Both trials
have suggested a curative potential of HDT-ASCT in young
PCNSL patients. This concept, supplemented by rituximab
immunotherapy, was evaluated in a phase II trial (Clinical-
Trials.gov Identifier: NCT00647049). Preliminary results
revealed an ORR of 91 % (77 % CR and 14 % PR) for pa-
tients treated with HDT-ASCT (n = 73) [13]. After a me-
dian follow-up of 35 months, the 3-year OS was 77.6 % for
all patients and 87.1 % for patients after HDT-ASCT. In
light of these findings, we initiated an ongoing international
randomized phase-II trial in collaboration with the IELSG.
This trial has 2 randomizations: in the 1st randomization
patients are allocated to primary chemotherapy with HD-
MTX and HD-Ara-C with or without thiotepa, and with or
without rituximab. The second randomization allocates to
consolidation therapy with WBRT vs. HDT-ASCT (Clini-
calTrials.gov Identifier: NCT01011920). In this trial, we aim
to determine the best induction treatment as well as the
superiority of HDT-ASCT or WBRT (the current standard
for consolidation after HD-MTX-based systemic treatment)
as consolidation treatment. First results of the randomized
phase II IELS32 trial show that the addition of thiotepa and
rituximab to MTX and Ara-C is associated with signifi-
cantly improved CRR and ORR [8]. The efficacy of HDT-
ASCT has been shown in several phase II trials in PCNSL
patients, both as upfront and salvage therapy, and has
yielded promising results concerning response and survival
rates [5, 6, 14–16]. However, as there have been no ran-
domized trials demonstrating a benefit of this concept over
conventional optimized combination chemotherapy, we de-
signed the MATRix trial to determine whether HDT-ASCT
is superior to conventional-dose chemoimmunotherapy (R-
DeVIC) as consolidation after intensified induction treat-
ment in patients with newly-diagnosed PCNSL.
Methods
Study design
This is a randomized, controlled, open-label, international
phase III trial with 2 parallel arms comparing HDT-ASCT
with conventional chemotherapy for consolidation in
newly diagnosed primary CNS lymphoma. Patients will be
recruited from 35 centers in Germany. Furthermore the
International Extranodal Lymphoma Study Group
(IELSG) will participate in the study and recruit patients.
Approval and permission to conduct the study was ob-
tained from all participating centers. The study protocol
was approved by the leading ethics committee (Ethik-
Kommission Landesärztekammer Baden Württemberg)
and the local ethics committees. A complete list of the
committees that approved the study is given in the Sup-
plementary Material (see Additional file 1: Table S1). The
protocol was also subject to authorization by the compe-
tent authorities as mandatory by federal law. All partici-
pants have to provide written informed consent. The trial
was assigned the EudraCT number 2012-000620-17 and
is registered at German clinical trials registry (DRKS0000
5503, registration date 22 April 2014) and ClinicalTrials.-
gov (NCT02531841, registration date 24 August 2015).
The SPIRIT checklist of the trial is given in the Supple-
mental Material (see Additional file 2).
Study objectives and endpoints
The primary objective of the MATRix trial is to demon-
strate superior efficacy of HDT-ASCT compared to
conventional chemotherapy. The primary endpoint of
this study is PFS, defined as time from the date of
randomization to the date of lymphoma progression, re-
lapse or death from any cause with possible censoring at
the date of last visit of follow-up.
Secondary endpoints include complete remission rate
(CRR) on day 60 after randomization; duration of re-
sponse (time from CR, unconfirmed CR or PR until
relapse, death or last follow-up visit); OS; and quality of
life (QOL, according to EORTC QLQ-C30). Secondary
safety endpoints are (serious) adverse events, toxicity
(according to NCI-CTCAE v.4.0) and neurotoxicity (ac-
cording to Mini-Mental State Examination (MMSE),
EORTC QLQ-BN20 and neuro-psychological battery).
Eligibility criteria
Immunocompetent patients with newly-diagnosed PCNSL
of B-cell immunophenotype, aged 18–65 years with an
ECOG Performance Status ≤3, or 66–70 years with an
ECOG Performance Status ≤2 are eligible. Randomization
is limited to patients demonstrating a successful stem cell
harvest, response to treatment, and confirmation of diag-
nosis by the central pathological review. For further details
on inclusion and exclusion criteria please see Table 1.
Randomization methodology
A randomized design (block randomization with randomly-
varying block sizes with an allocation ratio of 1:1) is applied
in order to ensure comparability of the treatment groups.
Central randomization by fax will be performed to guaran-
tee concealment of the treatment allocation. Stratification
according to response status (CR or PR) after 4 courses of
induction chemotherapy will be performed. Patients with
SD or PD after induction treatment will be treated off-
study. No stratification by study centers will take place,
because many centers having small numbers of patients will
be included in the trial. Randomization will take place after
4 cycles of induction therapy, i.e. immediately before start-
ing treatment with either HDT-ASCT or R-DeVIC in order
to enable an analysis according to the intention-to-treat
(ITT) principle with as few protocol violators or drop-outs
as possible. The block lengths will be documented
separately and will not be disclosed to the centers. The
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randomization code will be produced by validated pro-
grams based on the Statistical Analysis System (SAS®).
Treatment schedule
The treatment schedule is summarized in Fig. 1 (Interven-
tion Scheme). Randomization to either the conventional
consolidation (arm A) or HCT-ASCT consolidation (arm
B) will take place after 4 cycles of induction therapy after
re-checking inclusion/exclusion criteria and checking the
randomization criteria.
Induction treatment
Induction treatment consists of four cycles (every 3 weeks)
of induction chemotherapy similar to the MATRix regi-
men [8]. Rituximab will be given intravenously at 375 mg/
m2 on day 0 and 5 of each cycle. High-dose MTX will be
administered on day 1 of each induction treatment cycle
intravenously at 0.5 g/m2 in 15 min and then 3 g/m2 as a
3-h infusion. Cytarabine will be given intravenously at 2 g/
m2 over 1 h, twice a day (every 12 h) on two consecutive
days (days 2 and 3). Thiotepa will be given intravenously
at 30 mg/m2 over 30 min on day 4 during induction
chemotherapy. Stem-cell harvest will be performed
after the second cycle. The objective is to harvest a
minimum of 5 × 106 CD34+ cells/kg of body weight
with as few as possible leukapheresis sessions on con-
secutive days. CD34+ cells are to be collected, proc-
essed and stored according to conventional guidelines.
Consolidation treatment
Patients assigned to arm A will receive two cycles
(every 3 weeks) of conventional consolidation therapy
according to the R-DeVIC protocol: Rituximab
375 mg/m2 over 1.5 h on day 0; dexamethasone given
Table 1 Inclusion and exclusion criteria
Inclusion criteria 1. Immunocompetent patients with newly-diagnosed primary central nervous system B-cell lymphoma
2. Age 18–65 years irrespective of ECOG or 66–70 years (with ECOG Performance Status ≤2)
3. Histologically or cytologically assessed diagnosis of B-cell lymphoma by local pathologist.
4. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy
5. Disease exclusively located in the CNS
6. At least one measurable lesion
7. Previously untreated patients (previous or ongoing steroid treatment admitted)
8. Sexually active patients of childbearing potential who agree to take adequate contraceptive measures during
study participation
9. Written informed consent obtained according to international guidelines and local laws by patient or authorized
legal representative in case patient is temporarily legally not competent due to his or her disease
Additional
randomization criteria
1. Sufficient stem cell harvest (≥ 5 x 106 CD34+ cells/kg of body weight)
2. Complete remission, unconfirmed complete remission or partial remission
3. Central pathology results confirming local results
Exclusion criteria 1. Congenital or acquired immunodeficiency
2. Systemic lymphoma manifestation (outside the CNS)
3. Isolated ocular lymphoma without manifestation in the brain parenchyma or spinal cord
4. Previous or concurrent malignancies with the exception of surgically cured carcinoma insitu of the cervix, carcinoma of
the skin or other kinds of cancer without evidence of disease for at least 5 years
5. Previous Non-Hodgkin lymphoma at any time
6. Inadequate bone marrow (platelet count decreased≥ CTC grade 1, anemia≥ CTC grade 1, neutrophil count
decreased≥ CTC grade 1), renal (creatinine clearance <60 ml/min), cardiac (ejection fraction decreased ≥ CTC grade 2),
or hepatic function (blood bilirubin increased≥ CTC grade 2, alanine aminotransferase increased≥ CTC grade 2, aspartate
aminotransferase increased≥ CTC grade 2 or gamma-GT increased≥ CTC grade 2)
7. HBsAg, anti-HBc or HCV positivity
8. HIV infection, previous organ transplantation or other clinical evident form of immunodeficiency
9. Concurrent treatment with other experimental drugs or participation in a clinical trial within the last thirty days before
the start of this study
10. Symptomatic coronary artery disease, cardiac arrhythmias uncontrolled with medication or myocardial infarction within
the last 6 months (New York Heart Association Class III or IV heart disease)
11. Severe non-compensated pulmonary disease (IVC <55 %, DLCO <40 %)
12. Third space fluid accumulation >500 ml
13. Hypersensitivity to study treatment or any component of the formulation
14. Taking any medications likely to cause interactions with the study medication
15. Known or persistent abuse of medication, drugs or alcohol
16. Patient without legal capacity and who is unable to understand the nature, significance and consequences of the
study and without designated legal representative
17. Persons who are in a relationship of dependency/employment to the sponsor and/ or investigator
18. Any familial, sociological or geographical condition potentially hampering compliance with the study protocol
and follow-up schedule
19. Concurrent (or planned) pregnancy or lactation
20. Fertile patients refusing to use safe contraceptive methods during the study
ECOG Eastern Cooperative Oncology Group Performance Status, CSF cerebrospinal fluid, CNS central nervous system, CTC common toxicity criteria, HBsAg hepatitis B surface
antigen, anti-HBc hepatitis B core antigen antibody, HCV hepatitis C virus, HIV human immunodeficiency virus, IVC inspiratory vital capacity, DLCO diffusing capacity of the
lung for carbon monoxide
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intravenously at a dose of 40 mg over 15 min (d1-3);
etoposide 100 mg/m2 over 2 h (d1-3); ifosfamide
1500 mg/m2 over 2 h (d1-3) and carboplatin 300 mg/
m2 over 1 h (d1).
Patients assigned to arm B will receive HCT-ASCT with
carmustine (BCNU) and thiotepa: BCNU 400 mg/m2 over
1 h on day −6, thiotepa 5 mg/kg over 2 h twice a day (every
12 h) on two consecutive days (days −5 and −4). If BCNU
is not available at the investigational site, busulfan (3.2 mg/
kg over 2 h on two consecutive days (days −8 and −7). Au-
tologous stem cell reinfusion will be performed according
to standard procedures on day 0.
Fig. 1 Intervention Scheme. Patients with PD after two cycles of induction treatment, PD or SD after four cycles, insufficient bone marrow recorvery after
chemotherapy or insufficient stem cell harvest are not eligible for randomization; patients with complete remission, unconfirmed complete remission or
partial remission after completion of therapy will undergo regular follow up; patients with stable disease or progressive disease after completion of therapy
will undergo salvage treatment according to investigator’s choice. PCNSL = primary central nervous system lymphoma; ECOG= Eastern Cooperative
Oncology Group Performance Status; d = day; MTX =methotrexate; AraC = cytarabine; HDT-ASCT = high-dose chemotherapy followed by autologous stem
cell transplantation; BCNU= carmustine,** if BCNU is not available at study site, busulfan can be used instead; PD = progressive disease; SD = stable disease;
PR = partial remission; CR = complete remission; uCR = unconfirmed complete remission
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Assessments and follow up
At each visit, the following parameters will be evaluated:
Eastern Cooperative Oncology Group (ECOG) Perform-
ance Status, vital signs, physical and a neurological exam-
ination, laboratory profile, and adverse events, which will
be graded according to NCI-CTCAE v.4.0.
Tumor response will be assessed following the IPCG
response criteria [17]. Response assessment by brain
MRI will be done after the second and fourth course
and on day 60 after randomization. After the end of
treatment, disease status will be assessed every 3 months
during the first 2 years, every 6 months during the follow-
ing 3 years, and annually thereafter. The trial flow chart
indicating the assessments during the trial and the follow
up period is given as appendix of the SPIRIT checklist in
the Supplemental Material (see Additional file 2).
Tumor size, location(s) (only at screening and in case
of PD) and manifestation (singular/multiple; only at
screening) will be evaluated at the aforementioned time
points. In case of multiple tumors, one reference tumor
will be measured, the response being evaluated by com-
parison to the screening MRI. Response evaluation dur-
ing the trial will be determined by an independent
radiological review committee not involved in the study
design and blinded to treatment assignment.
Sample size estimation
Sample size calculation is based on the primary endpoint
PFS. We are assuming that the PFS rate for patients
treated with the conventional intervention (arm A, R-
DeVIC) is approximately 50 % after 3 years. To compare
the two treatment groups, a hazard ratio of 1.8 of the
conventional intervention (R-DeVIC) versus the HCT-
ASCT (arm B) is considered clinically relevant. This
corresponds to a PFS rate after 3 years of 68 % in the
HCT-ASCT group (arm B). To detect a difference be-
tween arms A and B with a power of 80 % at a two-
sided significance level of 5 % under this assumption 92
PFS defining events are required. Assuming an exponen-
tial model for survival, an accrual period of 3 years and
an additional follow-up time of 2 years, we will need to
enroll at least 200 patients. With an expected drop-out
of 10 %, 220 patients will be randomized. Furthermore,
we anticipate that some patients (about 10 %) will fail to
achieve complete or partial remission during the first 4
chemotherapy cycles and will not be randomized. We
therefore assume we will have to include approximately
250 patients in the study (start induction treatment).
Statistical analysis
The primary analysis will be conducted according to the
intention-to-treat principle and will therefore be based
on the full analysis set (FAS). The FAS includes all ran-
domized patients in whom therapy after randomization
was started, and patients are analyzed as belonging to
their randomized arm, regardless of whether they re-
fused or discontinued therapy, or whether other protocol
deviations are known. Patients will be censored at the
time of last follow-up provided no event of interest has
occurred so that as many patients as possible can be in-
cluded in the analysis.
The primary endpoint PFS will be analyzed with a
multivariable Cox proportional hazards model, contain-
ing the randomized treatment as explanatory variable
adjusted for the stratification variable response status.
The test of the primary hypothesis (null hypothesis:
equality of PFS rates) will be conducted within this
model. The treatment effect will be described by the es-
timated hazard ratio from this model and will be pre-
sented with a two-sided 95 % confidence interval. The
null hypothesis will be rejected if the value 1 is not con-
tained in the two-sided 95 % confidence interval for the
hazard ratio describing the relation between treatment
groups. Additionally, the PFS rates will be estimated by
the Kaplan-Meier method.
The endpoint OS will be analyzed in the same way as
described for PFS. The endpoint CR rate will be ana-
lyzed as the dependent variable of a logistic regression
model with treatment assignment as independent vari-
able. The endpoint response duration will be estimated
with a Cox-regression model. Death without former pro-
gression will be analyzed as competing event. The
regression models allow the inclusion of further poten-
tially important prognostic factors. Details will be deter-
mined in a Statistical Analysis Plan (SAP) to be finalized
before the analysis starts. For the evaluation of CR on
day 60 after randomization, patients not completing
therapy will be counted as non-responders. With respect
to the endpoint QOL, the treatment groups will be com-
pared descriptively according to the EORTC manual. All
p-values from analyses of secondary endpoints will be
interpreted in a descriptive sense.
Further descriptive analyses will consider all patients
included in the trial, i.e. data from start of induction
therapy with Rituximab, HD-MTX, HD-Ara-C, and thio-
tepa will be analyzed. We will analyze PFS and OS start-
ing at registration for all patients, and we will consider
three groups (two treatment arms, not randomized).
Subgroup analyses
Subgroup analyses will be conducted based on response
status (CR versus PR) as evaluated by contrast enhanced
MRI at the time of randomization. Of note, response
status is a stratification factor, thus the number of pa-
tients with either CR or PR between the two arms will
very likely be balanced.
We hypothesize that particularly those patients with PR
will benefit more from the more aggressive approach
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HDT-ASCT than patients with CR, because patients who
do not respond completely after 4 cycles of conventional
chemotherapy might be suffering from a lymphoma that
is more resistant to conventional chemotherapy than the
lymphomas in those patients who had already achieved a
complete response. Therefore, the response status can
be considered as a surrogate for a certain lymphoma
biology that tends to be more aggressive, something not
yet well understood.
We will estimate these subgroup effects for PFS and
OS using Cox regression analyses including the follow-
ing variables in the models: treatment allocation and
response status at randomization. An appropriate inter-
action term (treatment allocation*response status) will
be added to the model. We will illustrate subgroup ef-
fects using forest plots and provide the P value for the
interaction test. Whether the number of events (around
7 per variable) suffices to designate OS will have to be
seen. If not, we will conduct the subgroup analyses only
for PFS. Based on the IELSG risk score, [18] we will
evaluate the prognostic impact (PFS and OS) of the fol-
lowing baseline variables at the time of study inclusion
before starting any chemotherapy: age (as continuous
variable), performance score (ECOG 0–1 versus
ECOG >1), liquor-protein elevation (yes versus no),
involvement of deep-brain structures (yes versus no),
and elevated serum LDH (yes versus no). We will use
Cox regression analyses without variable selection
procedures to explore these risk factors.
Quality assurance and safety
Our study data will be managed using the DAMAST
Version 9.2, a proprietary data management system
based on the software package SAS®, which has been de-
veloped, validated and is maintained by the Clinical
Trials Unit Freiburg (CTU). Double data entry will be
performed by two different persons (with the exception
of free text). SAS® software will be used to review the
data for completeness, consistency and plausibility.
Data Monitoring Committee
An independent Data Monitoring Committee (DMC)
will be established. The DMC will consist of two medical
scientists and one statistician with longstanding experi-
ence in clinical trials. The DMC’s function is to monitor
the study’s course and if necessary make recommenda-
tions to the steering committee for study discontinu-
ation, modification or continuation. The underlying
principles for the DMC are the patients' ethical and safety
aspects. It is the task of the DMC to examine whether the
study’s conduct is still ethically justifiable, whether security
of the patients is ensured and whether the study’s conduct
is acceptable. The DMC will be informed about adherence
to the protocol, patient recruitment, observed serious
adverse events and deaths by receiving the development
safety update reports (DSURs) at regular intervals. Recom-
mendations on further continuation or modification of
the study will be given to the steering committee. The
composition and responsibilities of the DMC, the struc-
ture and procedures of its meetings, and its relationship to
other key study team members (steering committee), will
be laid down in a separate DMC charter.
Discussion
Untreated PCNSL has a dismal prognosis; its median
survival time is approximately 3 months. Current treat-
ment strategies have improved survival and shown cura-
tive potential in a considerable number of patients.
Similar to other hematological diseases, the rationale for
consolidation in PCNSL is to eliminate minimal residual
disease. There is evidence that HDT-ASCT with carmus-
tine or busulfan and thiotepa is feasible and highly effect-
ive both in patients with newly-diagnosed and relapsed
PCNSL [5, 6, 14].
The rationale behind the impact of HDT-ASCT in
PCNSL is the delivery of blood brain barrier (BBB) pene-
trating agents into the CNS at several-fold higher con-
centrations than conventional therapy [11, 12]. The
efficacy of HDT-ASCT has been investigated in several
phase II trials for primary, relapsed, or refractory
PCNSL, revealing promising response and survival rates
[5, 6, 15, 16]. However, although urgently needed, there
have been no randomized trials demonstrating this con-
cept’s superiority to optimized, conventional-dose poly-
chemotherapy. The question we now aim to answer is
whether HDT-ASCT is superior to conventional therapy
as consolidation after intensified immunochemotherapy
in patients with newly-diagnosed PCNSL. Quality assur-
ance will be acquired by independent radiological and
pathologic review committees not involved in the study’s
conception as well as by a blinded data review under-
taken after the end of the recruitment period and the
planned follow-up period. Therefore our study follows
high-level methodological standards.
We have been chosen the DeVIC combination chemo-
therapy regimen for conventional consolidation, because
its components cross the BBB and consist of multidrug
resistant-unrelated agents. HD-MTX-based induction
chemotherapy has been optimized over the past years.
An international randomized phase-II-trial was recently
conducted in collaboration with the IELSG to determine
both the best induction treatment and the superiority of
HDT-ASCT over WBRT as consolidation treatment.
Apart from the expected hematological toxicity, the pre-
liminary data have revealed good tolerability and efficacy
of the combination of rituximab, HD-MTX, HD-Ara-C
and thiotepa (MATRIX regimen) as induction regimen
[8]. In comparison to the IELSG32 trial, the induction
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treatment schedule was modified by administering ritux-
imab on day 0 and +5. We assume that the application
of two doses of rituximab—one before and one after
chemotherapy - results in a superior intracerebral con-
centration compared to bi-weekly dosing.
Results of the MATRix trial are expected to provide
high-level evidence with regard to the best consolidation
treatment in newly diagnosed PCNSL.
Additional files
Additional file 1: Table S1. List of ethics committees. (PDF 32 kb)
Additional file 2: SPIRIT checklist. (PDF 552 kb)
Abbreviations
Anti-HBc: hepatitis B core antigen antibody; ASCT: autologous stem cell
transplantation; BBB: blood brain barrier; BCNU: carmustine;
BfArM: Bundesinstitut für Arzeimittel und Medizinprodukte; CR: complete
remission; CSF: cerebrospinal fluid; CTU: Clinical Trials Unit; d: day;
DLBCL: diffuse large B-cell lymphoma; DLCO: diffusing capacity of the lung
for carbon monoxide; ECOG: Eastern Cooperative Oncology Group; EORTC
QLQ-C30: European Organisation for Research and Treatment of Cancer
Questionnaire Core-30; HBsAg: hepatitis B surface antigen; HCV: hepatitis
C virus; HD-AraC: high-dose cytarabine; HD-MTX: high-dose methotrexate;
HDT: high-dose chemotherapy; HIV: human immunodeficiency virus;
IELSG: International Extranodal Lymphoma Study Group; IVC: inspiratory vital
capacity; MMSE: Mini-Mental State Examination; NCI-CTCAE: National Cancer
Institute - Common toxicity criteria; NHL: Non Hodgkin Lymphoma;
ORR: overall response rate; OS: overall survival; PCNSL: primary central
nervous system lymphoma; PD: progressive disease; PFS: progression free
survival; PR: partial remission; QoL: quality of life; R-DeVIC: dexamethasone,
etoposide, ifosfamide, carboplatin; RT: radiotherapy; (S)AE: (serious) adverse
event; SAP: statistical analysis plan; SAS: Statstical Analysis System; SD: stable
disease; uCR: unconfirmed complete remission.
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